Parity, postmenopausal estrogen use, and cardiovascular disease risk factors in American Indian women: The Strong Heart Study

Journal of Women's Health

Volumn 6, Issue 4, 1997, Pages 441-449

  Cowan, Linda D ^a,g   Go, Oscar T ^a   Howard, Barbara V ^b   Devereux, Richard B ^c   Pettitt, David J ^d   Fabsitz, Richard R ^e   Lee, Elisa T ^a   Welty, Thomas K ^f  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b Medlantic Research Institute   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f Aberdeen Area Indian Health Service   (United States)

^g UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; AMERICAN INDIAN; ANTHROPOMETRIC PARAMETERS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; ESTROGEN THERAPY; ETHNIC GROUP; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INTERVIEW; MULTIVARIATE ANALYSIS; NORMAL HUMAN; PARITY; PHYSICAL EXAMINATION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

EID: 0030826181     PISSN: 10597115     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.1997.6.441     Document Type: Article

References (37)

1. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102.
2. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756.
3. Ness RB, Harris T, Cobb J, et al. Number of pregnancies and the subsequent risk of cardiovascular disease. N Engl J Med 1993;328:1528.
4. Ness RB, Schotland HM, Flegal KM, Shofer FS. Reproductive history and coronary heart disease risk in women. Epidemiol Rev 1994;16:298.
5. Lee ET, Welty TK, Fabsitz RR, et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: Design and methods. Am J Epidemiol 1990;132:1141.
6. Stoddart M, Blake B, Fabsitz R, et al. Recruitment of American Indians in epidemiologic research - The Strong Heart Study [Abstract]. Presented at the 121st Annual Meeting of the American Public Health Association, San Francisco, CA, October 1993.
7. Lipid Research Clinics Program. Manual of laboratory operations. Vol 1. Washington, DC: US Department of Health, Education, and Welfare, 1975. (DHEW publication No. 75-828).
8. Morgan CR, Lazarow A. Immunoassay of insulin: Two antibody system. Plasma insulin levels in normal, subdiabetic and diabetic rats. Diabetes 1963;12: 115.
9. von Clauss A. Gerinnungsphysiologische Scnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237.
10. Welty TK, Lee ET, Yeh JL, et al. Cardiovascular disease risk factors among American Indians. The Strong Heart Study. Am J Epidemiol 1995;142:269.
11. World Health Organization. WHO Expert Committee on Diabetes Mellitus: Second report. Geneva, Switzerland: World Health Organization, 1980 (WHO Technical Report.Series No. 646).
12. Ness RB, Cosmatos I, Flegal KM. Gravidity and serum lipids among Hispanic women in the Hispanic Health and Nutrition Examination Survey. J Women's Health 1995;4:149.
13. Hemminki E, Brambilla DJ, McKinlay SM, Posner JG. Use of estrogens among middle-aged Massachusetts women. DICP Ann Pharmacother 1991;25:418.
14. Bush TL, Cowan LD, Barrett-Connor E, et al. Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-up Study. JAMA 1983;249:903.
15. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s. JAMA 1989;261:2095.
16. Harris RB, Laws A, Reddy VM, King A, Haskell WL. Are women using postmenopausal estrogens? A community survey. Am J Public Health 1990;80:1266.
17. Barrett-Connor E. Prevalence, initiation, and continuation of hormone replacement therapy. J Women's Health 1995;4:143.
18. McNamara PM. Natural history of menopause: The Framingham Study. J Cont Educ Obstet Gynecol 1978;20:29.
19. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103.
20. Kaye SA, Folsom AR, Prineas RJ, Potter JD, Gapstur SM. The association of body fat distribution with lifestyle and reproductive factors in a population study of postmenopausal women. Int J Obesity 1990;14:583.
21. Kritz-Silverstein D, Barrett-Connor E, Wingard DL. The relationship between multiparity and lipoprotein levels in older women. J Clin Epidemiol 1992;45:761.
22. Hubert HB, Baker ED, Garrison RJ, Castelli WP. Lifestyle correlates of risk factor change in young adults: An eight-year study of coronary heart disease risk factors in the Framingham offspring. Am J Epidemiol 1987;125:812.
23. Manson JE, Rimm EB, Colditz GA, et al. Parity and incidence of non-insulin-dependent diabetes mellitus. Am J Med 1992;93:13.
24. Charles MA, Pettitt DJ, McCance DR, Hanson RL, Bennett PH, Knowler WC. Gravidity, obesity, and non-insulin-dependent diabetes among Pima Indian women. Am J Med 1994;97:250.
25. Simmons D, Williams R. Parity, ethnic group and the prevalence of non-insulin-dependent diabetes: The Coventry Diabetes Study [Abstract]. Diabetes 1991; 40(Suppl 1):497A.
26. Roumain JML, de Courten MP, Brodie TD, Hanson RL. NIDDM is associated with menstrual irregularity in Pima Indian women [Abstract]. Diabetes 1995;44 (Suppl 1), 181A.
27. Wahl P, Walden C, Knopp R, et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983;308:862.
28. Oliver MF, Boyd GS. The influence of sex hormones on the circulating lipids and lipoproteins in coronary sclerosis. Circulation 1956;13:82.
29. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991;91:191.
30. Lee AJ, Lowe GDO, Smith WCS, Tunstall-Pedoe H. Plasma fibrinogen in women: Relationships with oral contraception, the menopause and hormone replacement therapy. Br J Haematol 1993;83:616.
31. Meilahn EN, Cauley JA, Tracy RP, Macy EO, Gutai JP, Kuller LH. Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Am J Epidemiol 1996;143: 159.
32. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199.
33. Bradley DD, Wingerd J, Petitti DB, et al. Serum high-density lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. N Engl J Med 1978;299:17.
34. Wallace RB, Hoover J, Barrett-Connor E, et al. Altered plasma lipid and lipoprotein levels associated with oral contraceptive and oestrogen use. Lancet 1979; 2:112.
35. Cauley JA, LaPorte RE, Kuller LH, et al. Menopausal estrogen use, high density lipoprotein cholesterol subfractions and liver function. Atherosclerosis 1983; 49:31.
36. Furman RH, Alaupovic P, Howard RP. Effects of androgens and estrogens on serum lipids and the composition and concentration of serum lipoproteins in normolipidemic and hyperlipidemic states. Prog Biochem Pharmacol 1967;2:215.
37. Beral V. Long-term effects of childbearing on health. J Epidemiol Community Health 1985;39:343.